|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,237.70 INR | +3.44% |
|
-0.35% | +1.88% |
| 27/02 | Mankind Pharma says tax penalty of 10.2 million rupees dropped | RE |
| 16/02 | Mankind Pharma says tax penalty of 4.6 million rupees dropped | RE |
Business description: Mankind Pharma Limited
Number of employees: 19,620
Sales by Activity: Mankind Pharma Limited
| Fiscal Period: March | 2021 (INR) | 2022 (INR) | 2023 (INR) | 2024 (INR) | 2025 (INR) |
|---|---|---|---|---|---|
Pharmaceuticals | 6.22TCr | 7.78TCr | 8.75TCr | 10TCr | 12TCr |
Geographical breakdown of sales: Mankind Pharma Limited
| Fiscal Period: March | 2021 (INR) | 2022 (INR) | 2023 (INR) | 2024 (INR) | 2025 (INR) |
|---|---|---|---|---|---|
India | 6.03TCr | 7.59TCr | 8.45TCr | 9.52TCr | 11TCr |
Outside India | 185.9Cr | 186.81Cr | 295.83Cr | 813.46Cr | 1.53TCr |
Unallocated | 9.47Cr | - | - | - | - |
Executive Committee: Mankind Pharma Limited
| Manager | Title | Age | Since |
|---|---|---|---|
Sheetal Arora
CEO | Chief Executive Officer | 50 | 21/09/2007 |
Ashutosh Dhawan
DFI | Director of Finance/CFO | 57 | 03/03/2016 |
| Compliance Officer | 48 | 09/01/2025 | |
Chanakya Juneja
CTO | Chief Tech/Sci/R&D Officer | - | 15/11/2019 |
Pramod Gokhale
CTO | Chief Tech/Sci/R&D Officer | - | 14/05/2010 |
Composition of the Board of Directors: Mankind Pharma Limited
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | 03/07/1991 | |
Rajeev Juneja
BRD | Director/Board Member | 60 | 22/12/1992 |
Sheetal Arora
BRD | Director/Board Member | 50 | 21/09/2007 |
Bharat Anand
BRD | Director/Board Member | 49 | 31/08/2018 |
| Director/Board Member | 52 | 23/09/2016 | |
| Director/Board Member | 71 | 01/01/2020 | |
Vivek Kalra
BRD | Director/Board Member | 62 | 01/08/2022 |
Vijaya Sampath
BRD | Director/Board Member | 72 | 01/08/2022 |
| Director/Board Member | 71 | - |
Company details: Mankind Pharma Limited
Mankind Pharma Ltd.
262, Okhla Industrial Estate
110020, New Delhi
+91 11 4684 6700
http://www.mankindpharma.com
Group companies: Mankind Pharma Limited
| Name | Category and Sector |
|---|---|
Copmed Pharmaceuticals Pvt Ltd. | |
Copmed Pharmaceuticals Pvt Ltd. |
Other Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.44% | -0.35% | -3.38% | - | 969.34Cr | |
| -0.70% | -1.63% | +15.15% | +216.03% | 90TCr | |
| +0.46% | -1.95% | +46.21% | +61.14% | 58TCr | |
| -0.19% | -3.09% | +5.94% | +54.06% | 40TCr | |
| +0.84% | -7.63% | +9.19% | +26.92% | 34TCr | |
| +0.33% | -6.12% | +20.89% | +61.57% | 31TCr | |
| +1.47% | -3.92% | +21.39% | +34.86% | 30TCr | |
| -0.02% | -3.56% | +23.71% | +8.82% | 29TCr | |
| -0.41% | -2.66% | +15.57% | +66.27% | 20TCr | |
| +1.32% | -0.98% | +26.53% | +88.17% | 18TCr | |
| Average | +0.70% | -3.53% | +18.12% | +68.65% | 35.2TCr | |
| Weighted average by Cap. | +0.16% | -3.10% | +20.98% | +91.93% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MANKIND Stock
- Company Mankind Pharma Limited
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition